Secukinumab is a fully human recombinant monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A). It is an immunomodulatory biological active pharmaceutical ingredient belonging to the IgG1/κ monoclonal antibody class. Secukinumab is marketed under the brand name Cosentyx and is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Unlike conventional small-molecule APIs, Secukinumab API is a complex recombinant protein and requires biologics-specific manufacturing and analytical characterization. FDA identifies secukinumab as a fully human monoclonal antibody with an approximate molecular weight of 147.9 kDa and the chemical composition represented by C6854H10134N1754O2042S44.
EMA characterization reports that the secukinumab light chain contains 215 amino acids and the heavy chain contains 457 amino acids. The calculated molecular mass without post-translational modifications, including C-terminal lysines, is approximately 147,944 Da; after removal of the C-terminal lysines, the molecular mass is approximately 147,688 Da. The heavy chains are glycosylated at Asn307.
Secukinumab is an IL-17A antagonist used in the treatment of several inflammatory and immune-mediated disorders. Current U.S. labeling includes indications for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and enthesitis-related arthritis. U.S. labeling also includes hidradenitis suppurativa.
The European Medicines Agency lists Cosentyx for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa, with applicable adult and pediatric indications depending on the condition.
Secukinumab selectively binds to human IL-17A and inhibits its interaction with the IL-17 receptor. IL-17A contributes to inflammatory signaling and stimulates the production of additional inflammatory cytokines and chemokines. By neutralizing IL-17A activity, secukinumab reduces IL-17A-mediated inflammatory responses involved in diseases such as psoriasis and psoriatic arthritis.
Secukinumab is produced through recombinant DNA technology using a CHO cell expression system. EMA reports that the active substance is expressed in the CHO-HPT1 cell line. Manufacturing of this type of monoclonal-antibody API involves controlled cell culture, harvest, purification, viral safety controls, concentration and formulation-related processing.
Because Secukinumab is a glycosylated biological molecule, manufacturing consistency depends on control of critical quality attributes such as molecular identity, protein concentration, purity, aggregates, fragments, charge variants, glycosylation and biological activity.
Quality control for Secukinumab differs substantially from conventional chemical APIs. EMA describes control strategies involving size-exclusion chromatography (SEC) for monomer, aggregates and fragments, cation-exchange chromatography (CEX) for charge variants and CE-SDS for molecular integrity and purity. The proposed specifications were assessed as appropriate for routine control of the monoclonal antibody.
FDA describes the biological activity assay for secukinumab as measuring its ability to inhibit IL-17-induced IL-6 release from an immortalized human C-20/A4 chondrocyte cell line. Potency results are expressed relative to a reference standard.
Additional quality attributes for recombinant monoclonal antibodies can include host-cell proteins, residual host-cell DNA, endotoxin, microbial quality, charge heterogeneity, aggregates, fragments and other process-related impurities.
Secukinumab is a human IgG1/κ monoclonal antibody with an approximate molecular weight of 147.9 kDa. It contains two heavy chains and two light chains connected by disulfide bonds. The heavy chains contain an N-linked glycosylation site at Asn307.
The current U.S. finished product is available in several strengths and dosage forms, including 150 mg/mL, 75 mg/0.5 mL, 300 mg/2 mL subcutaneous presentations and 125 mg/5 mL intravenous infusion presentation. The liquid formulations have a reported pH of approximately 5.8. These values describe the finished medicinal product and should not be represented as universal drug-substance release specifications.
The finished Cosentyx product is supplied in appropriate pharmaceutical container-closure systems, including prefilled syringes, pens and vials. EMA describes Type I glass systems for the finished product. Finished-product storage is refrigerated according to the applicable labeling; drug-substance storage conditions should instead follow validated stability data and the applicable manufacturing specification.
Typical documentation for Secukinumab biological API may include:
A qualified Secukinumab API manufacturer requires appropriate biologics manufacturing infrastructure, recombinant CHO-cell production capabilities and validated purification and analytical processes. Because Secukinumab is a complex monoclonal antibody, consistent control of molecular identity, purity, aggregation, charge variants, glycosylation, potency and process-related impurities is essential for pharmaceutical-quality production. Regulatory assessments have found the established Secukinumab manufacturing and control strategy suitable for ensuring product consistency.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |